Alcon's Q1 Sales Jump 10%, Core EPS Rises to $0.85; New $1.5B Share Buyback Authorized
ALC is trading near its 52-week low of $71.55 (6.1% above the low).
Summary
Alcon reported strong first-quarter 2026 results, with sales increasing 10% on a reported basis to $2.7 billion and core diluted EPS rising to $0.85. The company also announced a new $1.5 billion share repurchase authorization over three years, signaling confidence in its financial position and commitment to shareholder returns. Management attributed the robust performance to new product launches, including Unity, Tryptyr, PanOptix Pro, and Precision7, which are driving momentum in both Surgical and Vision Care segments. This positive earnings report, coupled with a significant capital return program, is likely to be viewed favorably by investors. Traders will monitor the continued performance of these new products and the execution of the share repurchase program.
At the time of this announcement, ALC was trading at $75.92 on NYSE in the Life Sciences sector, with a market capitalization of approximately $37.2B. The 52-week trading range was $71.55 to $98.56. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.